$RFL
Rafael Holdings Inc Stock $rfl

$rfl Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000121390022067711 Filed on October 31, 2022

Income Statement

Concept	2022 Q3	2022	2021 Q3
Revenue	$69.00K	$410.0K	$969.0K
YoY Change	-92.88%	-89.68%	-21.85%
Cost Of Revenue		$3.499M
YoY Change		10.41%
Gross Profit		-$3.089M
YoY Change		-485.16%
Gross Profit Margin		-753.41%
Selling, General & Admin	$3.048M	$16.98M	$12.05M
YoY Change	-74.71%	-16.84%	333.49%
% of Gross Profit
Research & Development	$1.841M	$8.742M	$1.562M
YoY Change	17.86%	78.15%	47.36%
% of Gross Profit
Depreciation & Amortization	-$1.070M	$72.00K	$381.0K
YoY Change	-380.84%	-95.07%	-17.17%
% of Gross Profit
Operating Expenses	$4.907M	$25.72M	$13.99M
YoY Change	-64.93%	-3.97%	225.44%
Operating Profit		-$60.48M
YoY Change		114.47%
Interest Expense	$193.0K	$6.000K	$487.0K
YoY Change	-60.37%	-99.87%	-123.08%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.645M	-$140.0M	-$12.54M
YoY Change	-62.95%	456.97%	121.52%
Income Tax	-$6.000K	$0.00	$5.000K
% Of Pretax Income
Net Earnings	-$4.784M	-$140.5M	-$12.38M
YoY Change	-61.36%	472.63%	128.84%
Net Earnings / Revenue	-6933.33%	-34279.76%	-1277.61%
Basic Earnings Per Share		-$6.31
Diluted Earnings Per Share	-$242.0K	-$6.31	-$709.9K
COMMON SHARES
Basic Shares Outstanding		19.77M shares
Diluted Shares Outstanding		19.77M shares

Balance Sheet

Concept	2022 Q3	2022	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.24M	$63.24M	$7.854M
YoY Change	705.13%	705.13%	26.68%
Cash & Equivalents	$26.54M	$26.54M	$7.854M
Short-Term Investments	$36.70M	$36.70M
Other Short-Term Assets	$44.67M	$44.67M	$5.964M
YoY Change	648.91%	648.91%	80.73%
Inventory
Prepaid Expenses
Receivables	$447.0K	$447.0K	$346.0K
Other Receivables	$0.00	$0.00	$600.0K
Total Short-Term Assets	$108.3M	$108.3M	$14.76M
YoY Change	633.86%	633.86%	50.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.770M	$1.770M	$43.24M
YoY Change	-95.91%	-95.91%	-2.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.241M	$5.241M	$85.46M
YoY Change	-93.87%	-93.87%	8.32%
Other Assets	$1.387M	$1.387M	$1.517M
YoY Change	-8.57%	-8.57%	-5.19%
Total Long-Term Assets	$9.973M	$9.973M	$139.3M
YoY Change	-92.84%	-92.84%	10.11%
TOTAL ASSETS
Total Short-Term Assets	$108.3M	$108.3M	$14.76M
Total Long-Term Assets	$9.973M	$9.973M	$139.3M
Total Assets	$118.3M	$118.3M	$154.1M
YoY Change	-23.2%	-23.2%	13.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$564.0K	$633.0K	$1.296M
YoY Change	-56.48%	-51.16%	44.0%
Accrued Expenses	$1.875M	$1.875M	$1.227M
YoY Change	52.81%	52.81%	2.25%
Deferred Revenue
YoY Change
Short-Term Debt	$15.00M	$15.00M	$14.53M
YoY Change	3.25%	3.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.03M	$21.03M	$17.30M
YoY Change	21.52%	21.52%	203.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$88.00K	$88.00K	$48.00K
YoY Change	83.33%	83.33%	-52.0%
Total Long-Term Liabilities	$88.00K	$88.00K	$48.00K
YoY Change	83.33%	83.33%	-52.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.03M	$21.03M	$17.30M
Total Long-Term Liabilities	$88.00K	$88.00K	$48.00K
Total Liabilities	$21.11M	$17.81M	$31.77M
YoY Change	-33.54%	-43.95%	62.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$165.5M		-$40.80M
YoY Change	305.54%
Common Stock	$8.000K		$8.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$100.5M	$100.5M	$122.3M
YoY Change
Total Liabilities & Shareholders Equity	$118.3M	$118.3M	$154.1M
YoY Change	-23.2%	-23.2%	13.03%

Cashflow Statement

Concept	2022 Q3	2022	2021 Q3
OPERATING ACTIVITIES
Net Income	-$4.784M	-$140.5M	-$12.38M
YoY Change	-61.36%	472.63%	128.84%
Depreciation, Depletion And Amortization	-$1.070M	$72.00K	$381.0K
YoY Change	-380.84%	-95.07%	-17.17%
Cash From Operating Activities	-$1.902M	-$26.08M	-$6.981M
YoY Change	-72.75%	67.16%	313.08%
INVESTING ACTIVITIES
Capital Expenditures	$85.00K	-$2.000K	$31.00K
YoY Change	174.19%	-99.03%	-177.5%
Acquisitions
YoY Change
Other Investing Activities	-$6.462M	-$63.79M	$500.0K
YoY Change	-1392.4%	700.93%	-200.0%
Cash From Investing Activities	-$6.377M	-$63.80M	$531.0K
YoY Change	-1300.94%	680.76%	-198.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$99.17M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.997M	$103.9M	14.53M
YoY Change	-58.72%	242.81%
NET CHANGE
Cash From Operating Activities	-1.902M	-$26.08M	-6.981M
Cash From Investing Activities	-6.377M	-$63.80M	531.0K
Cash From Financing Activities	5.997M	$103.9M	14.53M
Net Change In Cash	-2.282M	$13.68M	8.078M
YoY Change	-128.25%	109.67%	-462.24%
FREE CASH FLOW
Cash From Operating Activities	-$1.902M	-$26.08M	-$6.981M
Capital Expenditures	$85.00K	-$2.000K	$31.00K
Free Cash Flow	-$1.987M	-$26.08M	-$7.012M
YoY Change	-71.66%	69.39%	324.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments		usd
CY2021	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments		usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.22
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.11
CY2022	rfl	Contribution From Noncontrolling Interest Of Consolidated Entity ContributionFromNoncontrollingInterestOfConsolidatedEntity		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.31
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19767342	shares
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits		usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss		usd
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments		usd
CY2021	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
CY2021	rfl	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty		usd
CY2022	rfl	Impairment Altira ImpairmentAltira		usd
CY2021	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit		usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	14500000	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2021	rfl	Provision For Losses On Related Party Receivables ProvisionForLossesOnRelatedPartyReceivables		usd
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55863
CY2022	dei	Entity Registrant Name EntityRegistrantName	RAFAEL HOLDINGS, INC.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Newark
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-07-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2296593
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Broad Street
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07102
CY2022	dei	City Area Code CityAreaCode	(212)
CY2022	dei	Local Phone Number LocalPhoneNumber	658-1450
CY2022	dei	Security12b Title Security12bTitle	Class B common stock, par value $0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	RFL
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	70200000	usd
CY2022	dei	Auditor Firm AuditorFirmId	596
CY2022	dei	Auditor Name AuditorName	CohnReznick LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	26537000	usd
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	7854000	usd
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	5000000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	36698000	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	140000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	197000	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	193000	usd
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	157000	usd
CY2021Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	235000	usd
CY2022Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	720000	usd
CY2021Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	0	usd
CY2021Q3	rfl	Due From Rafael Pharmaceuticals DueFromRafaelPharmaceuticals	600000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4621000	usd
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1075000	usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	40194000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	108347000	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	14764000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1770000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1840000	usd
CY2021Q3	rfl	Equity Investment Rp Finance EquityInvestmentRPFinance	575000	usd
CY2022Q3	rfl	Accounts Receivable Related Parties Current One AccountsReceivableRelatedPartiesCurrentOne	9375000	usd
CY2021Q3	rfl	Accounts Receivable Related Parties Current One AccountsReceivableRelatedPartiesCurrentOne	0	usd
CY2021Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	7500000	usd
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	79141000	usd
CY2022Q3	rfl	Investments Other Pharmaceuticals InvestmentsOtherPharmaceuticals	477000	usd
CY2021Q3	rfl	Investments Other Pharmaceuticals InvestmentsOtherPharmaceuticals	477000	usd
CY2022Q3	rfl	Investments Hedge Funds InvestmentsHedgeFunds	4764000	usd
CY2021Q3	rfl	Investments Hedge Funds InvestmentsHedgeFunds	5268000	usd
CY2022Q3	rfl	In Process Research And Development InProcessResearchAndDevelopment	1575000	usd
CY2021Q3	rfl	In Process Research And Development InProcessResearchAndDevelopment	1575000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1387000	usd
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1517000	usd
CY2021Q3	rfl	Noncurrent Assets Heldforsale NoncurrentAssetsHeldforsale	41398000	usd
CY2022Q3	us-gaap	Assets Assets	118320000	usd
CY2021Q3	us-gaap	Assets Assets	154055000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	564000	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1160000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1875000	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1227000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3518000	usd
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	252000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	69000	usd
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	136000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	15000000	usd
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	14528000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21026000	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17303000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	88000	usd
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	21114000	usd
CY2021Q3	us-gaap	Liabilities Liabilities	17351000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2022Q3	rfl	Common Stock Value1 CommonStockValue1	237000	usd
CY2021Q3	rfl	Common Stock Value1 CommonStockValue1	169000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	262023000	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159136000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165457000	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40799000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-63000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	3767000	usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	3772000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	100515000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	122286000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-3309000	usd
CY2021Q3	us-gaap	Minority Interest MinorityInterest	14418000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97206000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	136704000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118320000	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	154055000	usd
CY2022	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	179000	usd
CY2021	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	214000	usd
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	111000	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	108000	usd
CY2022	rfl	Revenues Other Related Party RevenuesOtherRelatedParty	120000	usd
CY2021	rfl	Revenues Other Related Party RevenuesOtherRelatedParty	480000	usd
CY2022	us-gaap	Revenues Revenues	410000	usd
CY2021	us-gaap	Revenues Revenues	802000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16978000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17024000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8742000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4907000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	72000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	70000	usd
CY2022	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit	25000000	usd
CY2022	rfl	Provision For Losses On Related Party Receivables ProvisionForLossesOnRelatedPartyReceivables	10095000	usd
CY2021	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	7000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-60477000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-28199000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6000	usd
CY2021	us-gaap	Interest Expense InterestExpense	12000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	201000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	2000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	749000	usd
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	724000	usd
CY2022	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	79141000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-45000	usd
CY2022	rfl	Unrealized Gain On Investments Hedge Fund UnrealizedGainOnInvestmentsHedgeFund	504000	usd
CY2021	rfl	Unrealized Gain On Investments Hedge Fund UnrealizedGainOnInvestmentsHedgeFund	-4758000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139972000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23426000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-575000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	383000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-140547000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23061000	usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-1830000	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-1705000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1830000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1705000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-24766000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17719000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-222000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-124658000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24544000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-24766000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	-63000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	5000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-10000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-142445000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-24756000	usd
CY2022	rfl	Comprehensive Loss Attributable To Noncontrolling Interests ComprehensiveLossAttributableToNoncontrollingInterests	-17746000	usd
CY2021	rfl	Comprehensive Loss Attributable To Noncontrolling Interests ComprehensiveLossAttributableToNoncontrollingInterests	-37000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-124699000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24793000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-140547000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-23061000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-17719000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-222000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-122828000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-22839000	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1830000	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1705000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.22
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.38
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.09
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.11
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.31
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19767342	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16522686	shares
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	136704000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18061000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	18978000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99170000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-6228000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10997000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	75000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-63000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97206000	usd
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	130528000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-24766000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6633000	usd
CY2021	rfl	Stock Issued During Period Shares Issued Investment StockIssuedDuringPeriodSharesIssuedInvestment	8501000	usd
CY2021	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	13000000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	185000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2000000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	71000	usd
CY2021	rfl	Capital Contribution For Noncontrolling Interest CapitalContributionForNoncontrollingInterest	912000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	136704000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-24766000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1830000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1705000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-140547000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-23061000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	72000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	70000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	6000	usd
CY2022	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	-504000	usd
CY2021	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	4758000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-45000	usd
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	724000	usd
CY2022	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	79141000	usd
CY2021	rfl	Impairment Altira ImpairmentAltira	-7000000	usd
CY2022	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit	25000000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-575000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	383000	usd
CY2022	rfl	Provision For Losses On Related Party Receivables ProvisionForLossesOnRelatedPartyReceivables	10095000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	193000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	-917000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6633000	usd
CY2021	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	749000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	140000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-74000	usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	161000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3545000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	802000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-130000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-63000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	52000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	164000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3566000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	137000	usd
CY2022	rfl	Common Shares Issued For Payment Of Purchase Price For Altira Equity CommonSharesIssuedForPaymentOfPurchasePriceForAltiraEquity		usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-67000	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	136000	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	482000	usd
CY2022	rfl	Increase Decrease In Due From Rafael Pharmaceuticals IncreaseDecreaseInDueFromRafaelPharmaceuticals	120000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-40000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	44000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26038000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15314000	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-41000	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-287000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26079000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15601000	usd
CY2022	rfl	Purchases Dispositions Of Property And Equipment PurchasesDispositionsOfPropertyAndEquipment	-2000	usd
CY2021	rfl	Purchases Dispositions Of Property And Equipment PurchasesDispositionsOfPropertyAndEquipment	44000	usd
CY2022	rfl	Payment To Fund Rp Finance Line Of Credit PaymentToFundRPFinanceLineOfCredit	1875000	usd
CY2021	rfl	Payment To Fund Rp Finance Line Of Credit PaymentToFundRPFinanceLineOfCredit	7500000	usd
CY2022	rfl	Payment To Rafael Pharmaceuticals Pursuant To Line Of Credit PaymentToRafaelPharmaceuticalsPursuantToLineOfCredit	25000000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	65306000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	28500000	usd
CY2021	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	3658000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7000000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2000000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9123000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-63683000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7921000	usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-113000	usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-250000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63796000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8171000	usd
CY2021	rfl	Contribution From Noncontrolling Interest Of Consolidated Entity ContributionFromNoncontrollingInterestOfConsolidatedEntity	912000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	71000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99170000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13000000	usd
CY2022	rfl	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty	10997000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	-6228000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	75000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	185000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	103864000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15798000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122000	usd
CY2021	rfl	Acquisition Of Additional Ownership Interest In Lipo Medix AcquisitionOfAdditionalOwnershipInterestInLipoMedix		usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	103864000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30298000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-306000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13683000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6648000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12854000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6206000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26537000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12854000	usd
CY2021	rfl	Common Shares Issued For Payment Of Purchase Price For Altira Equity CommonSharesIssuedForPaymentOfPurchasePriceForAltiraEquity	8501000	usd
CY2022	rfl	Acquisition Of Additional Ownership Interest In Lipo Medix AcquisitionOfAdditionalOwnershipInterestInLipoMedix	8000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26537000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7854000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	5000000	usd
CY2022Q3	rfl	Total Cash And Cash Equivalent And Restricted Cash Shown In Statement Of Cash Flows TotalCashAndCashEquivalentAndRestrictedCashShownInStatementOfCashFlows	26537000	usd
CY2021Q3	rfl	Total Cash And Cash Equivalent And Restricted Cash Shown In Statement Of Cash Flows TotalCashAndCashEquivalentAndRestrictedCashShownInStatementOfCashFlows	12854000	usd
CY2022Q3	rfl	Outstanding Capital Stock OutstandingCapitalStock	0.51	pure
CY2022Q3	rfl	Capital Stock CapitalStock	0.41	pure
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
CY2022Q3	us-gaap	Other Minority Interests OtherMinorityInterests	79100000	usd
CY2022	rfl	Interest Amount interestAmount	10400000	usd
CY2022	rfl	Membership Interest Percentage MembershipInterestPercentage	0.33333	pure
CY2022Q3	us-gaap	Investments Investments	7000000	usd
CY2021	rfl	Impairment Charge ImpairmentCharge	7000000	usd
CY2020Q4	rfl	Membership Interest MembershipInterest	0.33	pure
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	383000	usd
CY2022Q3	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	26500000	usd
CY2022	rfl	Sale Securities SaleSecurities	36700000	usd
CY2022Q3	us-gaap	Alternative Investment AlternativeInvestment	4800000	usd
CY2022	rfl	Risk And Uncertainties RiskAndUncertainties	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Risks and Uncertainties - COVID-19, War in Ukraine</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In late 2019, a novel strain of coronavirus, SARS-CoV, which causes COVID-19, was identified and has proved to be highly contagious. It has since spread extensively throughout the world, including the United States, and was declared a global pandemic by the World Health Organization in March 2020. The Company actively monitors the outbreak, including the spread of new variants of interest, and its potential impact on the Company’s operations and those of the Company’s holdings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even with growing availability of testing and vaccines and the relaxation of public health measures that were implemented to limit the spread of the pandemic, there continues to be uncertainty around the COVID-19 pandemic and its impact.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had implemented a number of measures to protect the health and safety of the Company’s workforce including a voluntary work-from-home policy for the Company’s workforce who can perform their jobs from home as well as restrictions on discretionary business travel. Most of our employees have returned to working from the office on a part-time basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full impact of the COVID-19 pandemic on the Company will depend on factors such as the length of time of the pandemic; the responses of federal, state and local governments; the impact of future variants that may emerge; vaccination rates among the population; the efficacy of the COVID-19 vaccines; the longer-term impact of the pandemic on the economy and consumer behavior; and the effect on our employees, vendors, and other partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The short and long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time. The imposition of sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business and the companies in which we have investments, financial condition, and results of operations. Because of the highly uncertain and dynamic nature of these events, it is not currently possible to estimate the impact of the Russian – Ukraine war on our business and the companies in which we have investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of Credit Risk and Significant Customers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the year ended July 31, 2022, including revenue from discontinued operations, related parties represented 58% of the Company’s revenue, and as of July 31, 2022, two customers, one of which is a related party, represented 24% and 47% of the Company’s accounts receivable balance, respectively. For the year ended July 31, 2021, related parties represented 65% of the Company’s revenue, and as of July 31, 2021, two customers, one of which is a related party, represented 45% and 33% of the Company’s accounts receivable balance, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	5000000	usd
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses	4000	usd
CY2021	us-gaap	Provision For Other Losses ProvisionForOtherLosses	193000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	2683000	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	3392000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1317000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1390000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Real Estate Discontinued Operations GainLossOnDispositionOfRealEstateDiscontinuedOperations	-501000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Real Estate Discontinued Operations GainLossOnDispositionOfRealEstateDiscontinuedOperations	-1613000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	472000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	28000	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	157000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	1486000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	92000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1830000	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1705000	usd
CY2022	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	1830000	usd
CY2021	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	1705000	usd
CY2022	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	3250000	usd
CY2022Q3	us-gaap	Other Notes Payable OtherNotesPayable	15000000	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	33000000	usd
CY2019Q1	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	10000000	usd
CY2022	rfl	Percentage Of Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent	0.50	pure
CY2022	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	17300000	usd
CY2022Q3	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	45437000	usd
CY2022Q3	us-gaap	Land Land	10412000	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1145000	usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Other AssetsHeldForSaleNotPartOfDisposalGroupOther	205000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	57199000	usd
CY2022Q3	us-gaap	Property Subject To Or Available For Operating Lease Net PropertySubjectToOrAvailableForOperatingLeaseNet	17005000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	40194000	usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	40194000	usd
CY2022Q3	rfl	Total Assets Heldforsale TotalAssetsHeldforsale	40194000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	15000000	usd
CY2021Q3	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	45336000	usd
CY2021Q3	us-gaap	Land Land	10412000	usd
CY2021Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1145000	usd
CY2021Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Other AssetsHeldForSaleNotPartOfDisposalGroupOther	205000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	57098000	usd
CY2021Q3	us-gaap	Property Subject To Or Available For Operating Lease Net PropertySubjectToOrAvailableForOperatingLeaseNet	15700000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	41398000	usd
CY2021Q3	rfl	Noncurrent Assets Heldforsale NoncurrentAssetsHeldforsale	41398000	usd
CY2021Q3	rfl	Total Assets Heldforsale Noncurrent TotalAssetsHeldforsaleNoncurrent	41398000	usd
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	14528000	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	150000	usd
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	111000	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	1300000	usd
CY2021Q3	us-gaap	Other Assets OtherAssets	1500000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3499000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3169000	usd
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties		usd
CY2020Q3	us-gaap	Other Commitment OtherCommitment	5000000	usd
CY2020Q4	us-gaap	Other Commitment OtherCommitment	5000000	usd
CY2021Q2	us-gaap	Other Commitment OtherCommitment	10000000	usd
CY2021Q3	us-gaap	Other Commitment OtherCommitment	10000000	usd
CY2021Q3	us-gaap	Other Commitment OtherCommitment	5000000	usd
CY2022	rfl	Cumulative Funds Description CumulativeFundsDescription	As of July 31, 2022, the Company has funded a cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance.
CY2022	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	1900000	usd
CY2022	rfl	Issued And Outstanding Ordinary Shares Percentage IssuedAndOutstandingOrdinarySharesPercentage	0.84	pure
CY2021Q3	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.15	pure
CY2021Q4	us-gaap	Shares Issued SharesIssued	15975000	shares
CY2021Q4	rfl	Purchase Price PurchasePrice	0.1878	usd
CY2021Q4	rfl	Amount Of Aggregate Purchase Price AmountOfAggregatePurchasePrice	3000000	usd
CY2022Q3	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	8000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	45000	usd
CY2022Q3	us-gaap	Assets Designated To Closed Block Equity Securities Available For Sale At Fair Value AssetsDesignatedToClosedBlockEquitySecuritiesAvailableForSaleAtFairValue	36698000	usd
CY2022Q3	rfl	Hedge Funds HedgeFunds	4764000	usd
CY2022Q3	rfl	Available For Sale Securities Total AvailableForSaleSecuritiesTotal	41462000	usd
CY2021Q3	rfl	Hedge Funds HedgeFunds	5268000	usd
CY2021Q3	rfl	Available For Sale Securities Total AvailableForSaleSecuritiesTotal	5268000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139972000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23426000	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	5268000	usd
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	7510000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	-7000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-504000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	4758000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4764000	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	5268000	usd
CY2020Q4	rfl	Fair Value Estimate Not Practicable Cost Method Investment FairValueEstimateNotPracticableCostMethodInvestment	2000000	usd
CY2021Q2	rfl	Fair Value Estimate Not Practicable Cost Method Investment FairValueEstimateNotPracticableCostMethodInvestment	5000000	usd
CY2022Q3	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	500000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	700000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	196000	usd
CY2021Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	315000	usd
CY2022Q3	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	158000	usd
CY2021Q3	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	113000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	197000	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	193000	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	157000	usd
CY2021Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	235000	usd
CY2022Q2	us-gaap	Employee Stock Ownership Plan Esop Terms Of Repurchase Obligation EmployeeStockOwnershipPlanESOPTermsOfRepurchaseObligation	On June 22, 2022, the Company entered into a Stock Purchase Agreement (the “I9 SPA”) with I9 Plus, LLC. On July 6, 2022, pursuant to the I9 SPA, the Company sold 3,225,806 shares of the Company’s Class B common stock to I9 Plus, LLC at a price per share of $1.86 and an aggregate sale price of $6 million.
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	54900000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	35700000	usd
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	4900000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15559000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49096000	usd
CY2022	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	1021277	shares
CY2021	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	683414	shares
CY2022	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock	1507373	shares
CY2021	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock	1007975	shares
CY2021	rfl	Shares Issuable Upon Exercise Of Warrants SharesIssuableUponExerciseOfWarrants	26189	shares
CY2022	rfl	Total Total	2528650	shares
CY2021	rfl	Total Total	1717578	shares
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.80	pure
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-137978000	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-22546000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1994000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-880000	usd
CY2021Q3	us-gaap	Notes Payable NotesPayable	15000000	usd
CY2022	us-gaap	Long Term Debt Description LongTermDebtDescription	The Note Payable bears interest at a rate per annum equal to seven and one-quarter percent (7.25%) from July 9, 2021, through July 31, 2021 and thereafter at an interest rate per annum equal to the 30-day LIBOR Rate, as published in The Wall Street Journal, plus 6.90% per annum, but in no event less than seven and one-quarter percent (7.25%) per annum. The Note Payable is due on August 1, 2022, subject to the Company’s option to extend the maturity date until August 1, 2023 for a fee equal to three-quarters of one percent (0.75%) of the Note Payable.
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-11-01
CY2022Q3	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	$37,500
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	1200000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	64000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	472000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	28000	usd
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	343000	usd
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	322000	usd
CY2022Q3	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	69000	usd
CY2021Q3	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	136000	usd
CY2022Q3	us-gaap	Area Of Land AreaOfLand	80000	sqft
CY2022	rfl	Rent And Parking Expenses RentAndParkingExpenses	2100000	usd
CY2021	rfl	Rent And Parking Expenses RentAndParkingExpenses	2000000	usd
CY2022Q3	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	720000	usd
CY2021Q1	rfl	Description Of Warrant DescriptionOfWarrant	On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Cornerstone Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.
CY2022	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	The Company leases space to related parties (including IDT Corporation - see above) which represented approximately 58% and 65% for the years ended July 31, 2022 and 2021, respectively, which includes discontinued operations related party rental income pertaining to the 520 Property. The portion of related party rental income pertaining to the 520 Property has been classified in discontinued operations on the consolidated statements of operations and comprehensive loss for the years ended July 31, 2022 and 2021. See Note 18 for future minimum rent payments from related parties and other tenants.
CY2020Q2	rfl	Acquired An Additional Membership Interest AcquiredAnAdditionalMembershipInterest	0.33333	pure
CY2020Q4	rfl	Acquired An Additional Membership Interest AcquiredAnAdditionalMembershipInterest	0.33333	pure
CY2020Q4	rfl	Aggregate Of A Membership Interest AggregateOfAMembershipInterest	0.66666	pure
CY2022	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	575000	usd
CY2021	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	383000	usd
CY2020Q4	rfl	Warrants Percentage WarrantsPercentage	0.20	pure
CY2020Q4	rfl	Exercise Price ExercisePrice	22.91
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-19000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-18000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-18000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	29514000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4952000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	8752000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1571000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-35001000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6560000	usd
CY2022	rfl	Income Tax Reconciliation Foreign Income Tax Rates Differential IncomeTaxReconciliationForeignIncomeTaxRatesDifferential	459000	usd
CY2021	rfl	Income Tax Reconciliation Foreign Income Tax Rates Differential IncomeTaxReconciliationForeignIncomeTaxRatesDifferential	203000	usd
CY2022	rfl	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	-3632000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-92000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-184000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-18000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15170000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12495000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	31850000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	968000	usd
CY2022	us-gaap	Depreciation Depreciation	1000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	236000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1839000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2096000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	49096000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15559000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2022	rfl	Sale Of Building Description SaleOfBuildingDescription	The Real Estate segment consists of the Company’s real estate holdings, comprised of a portion of a commercial building in Israel.
CY2022	us-gaap	Revenues Revenues	410000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-60477000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139972000	usd
CY2021	us-gaap	Revenues Revenues	802000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-28199000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23426000	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.07	pure
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.07	pure
CY2022Q3	us-gaap	Noncurrent Assets NoncurrentAssets	1770000	usd
CY2022Q3	rfl	Total Asset TotalAsset	118320000	usd
CY2021Q3	us-gaap	Noncurrent Assets NoncurrentAssets	1840000	usd
CY2021Q3	rfl	Total Asset TotalAsset	154055000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6110000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	791000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	523000	usd
CY2022	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative	-18978000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	-917000	usd
CY2022	rfl	Lease Expiration Dates LeaseExpirationDates	The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.
CY2022	rfl	Comprehensive Income Loss Net Of Tax Attributable To Noncontrolling Interests ComprehensiveIncomeLossNetOfTaxAttributableToNoncontrollingInterests	300000	usd
CY2022	us-gaap	Loss Contingency Settlement Agreement Terms LossContingencySettlementAgreementTerms	As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021, which the Company has fully paid.
CY2021Q3	rfl	Restricted Stock Units Description RestrictedStockUnitsDescription	On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “Institutional Shares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses.
CY2022Q3	rfl	Supplemental Deferred Sale Price SupplementalDeferredSalePrice	6000000	usd
CY2022Q2	rfl	Employment Agreement Term EmploymentAgreementTerm	P5Y
CY2022Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	600000	usd
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	580874	shares
CY2020Q3	rfl	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePrice	4.9
CY2021	rfl	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P2Y7M24D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2846000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	118409	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	40.85
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14546	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.9
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1323	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.9
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	683414	shares
CY2021Q3	rfl	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePrice	11.13
CY2022	rfl	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26982000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	518304	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.54
CY2022	rfl	Weighted Average Remaining Contractual Termin Years Granted WeightedAverageRemainingContractualTerminYearsGranted	P9Y3M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	180441	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1021277	shares
CY2022Q3	rfl	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePrice	12.11
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y5M19D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	594607	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.69
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y21D
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6633000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.01	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y14D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	11000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M8D
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	33360	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	151000	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	986835	shares
CY2022Q1	rfl	Restricted Shares Vested Percentage RestrictedSharesVestedPercentage	0.24	pure
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	452130	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	123104	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	10.8
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	956317	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	48.34
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	69347	shares
CY2021	rfl	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodWeightedAverageGrantDateFairValue	-10.76
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	2099	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	13.54
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1007975	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	46.77
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1533311	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.24
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	90608	shares
CY2022	rfl	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodWeightedAverageGrantDateFairValue	16.86
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	943305	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	48.5
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1507373	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.22
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17270000	usd
CY2021	rfl	Comprehensive Income Loss Net Of Tax Attributable To Noncontrolling Interests ComprehensiveIncomeLossNetOfTaxAttributableToNoncontrollingInterests	300000	usd
CY2022	us-gaap	Amortization Of Deferred Property Taxes AmortizationOfDeferredPropertyTaxes	212000	usd
CY2021	us-gaap	Amortization Of Deferred Property Taxes AmortizationOfDeferredPropertyTaxes	37000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	75000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	77000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	78000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	230000	usd
CY2022	rfl	Related Party Leases Expire Description RelatedPartyLeasesExpireDescription	The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel.
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2000000	usd
CY2022	rfl	Related Parties Terminate Leases Description RelatedPartiesTerminateLeasesDescription	The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.
CY2022	rfl	Purchaser Receive Credit Amount PurchaserReceiveCreditAmount	15000000	usd
CY2022	us-gaap	Subsequent Event Effect Of Change In Tax Status SubsequentEventEffectOfChangeInTaxStatus	33000000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent		usd
CY2021Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2022Q3	rfl	Due From Rafael Pharmaceuticals DueFromRafaelPharmaceuticals		usd
CY2021Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2022Q3	rfl	Equity Investment Rp Finance EquityInvestmentRPFinance		usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2021	rfl	Provision For Losses On Related Party Receivables ProvisionForLossesOnRelatedPartyReceivables		usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
CY2021	rfl	Increase Decrease In Due From Rafael Pharmaceuticals IncreaseDecreaseInDueFromRafaelPharmaceuticals		usd
CY2021	rfl	Payment To Rafael Pharmaceuticals Pursuant To Line Of Credit PaymentToRafaelPharmaceuticalsPursuantToLineOfCredit		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash		usd
CY2021	us-gaap	Other General Expense OtherGeneralExpense		usd
CY2022	us-gaap	Other Income Tax Expense Benefit Continuing Operations OtherIncomeTaxExpenseBenefitContinuingOperations		usd
CY2021	us-gaap	Other Income Tax Expense Benefit Continuing Operations OtherIncomeTaxExpenseBenefitContinuingOperations		usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet		usd
CY2022	rfl	Shares Issuable Upon Exercise Of Warrants SharesIssuableUponExerciseOfWarrants		shares
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	rfl	Deferred State Expense Benefit DeferredStateExpenseBenefit		usd
CY2021	rfl	Deferred State Expense Benefit DeferredStateExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies		usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2021	rfl	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies		usd
CY2021	us-gaap	Depreciation Depreciation		usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals		usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2021Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021	rfl	Weighted Average Remaining Contractual Termin Years Granted WeightedAverageRemainingContractualTerminYearsGranted
CY2021Q3	rfl	Aggregate Intrinsic Value Outstanding Granted AggregateIntrinsicValueOutstandingGranted		usd
CY2021	rfl	Weighted Average Remaining Contractual Termin Years Exercised WeightedAverageRemainingContractualTerminYearsExercised
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021	rfl	Weighted Average Remaining Contractual Termin Years Cancelled Forfeited WeightedAverageRemainingContractualTerminYearsCancelledForfeited
CY2021Q3	rfl	Aggregate Intrinsic Value Cancelled Forfeited AggregateIntrinsicValueCancelledForfeited		usd
CY2022Q3	rfl	Aggregate Intrinsic Value Outstanding Granted AggregateIntrinsicValueOutstandingGranted		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022	rfl	Weighted Average Remaining Contractual Termin Years Cancelled Forfeited WeightedAverageRemainingContractualTerminYearsCancelledForfeited
CY2022Q3	rfl	Aggregate Intrinsic Value Cancelled Forfeited AggregateIntrinsicValueCancelledForfeited		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative		usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001713863

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-22-067711-index-headers.html	Edgar Link	pending
0001213900-22-067711-index.html	Edgar Link	pending
0001213900-22-067711.txt	Edgar Link	pending
0001213900-22-067711-xbrl.zip	Edgar Link	pending
f10k2022ex21-01_rafaelhold.htm	Edgar Link	pending
f10k2022ex23-1_rafaelhold.htm	Edgar Link	pending
f10k2022ex31-01_rafaelhold.htm	Edgar Link	pending
f10k2022ex31-02_rafaelhold.htm	Edgar Link	pending
f10k2022ex32-01_rafaelhold.htm	Edgar Link	pending
f10k2022ex32-02_rafaelhold.htm	Edgar Link	pending
f10k2022ex4-2_rafaelhold.htm	Edgar Link	pending
f10k2022_rafaelhold.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
f10k2022_rafaelhold_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rfl-20220731.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rfl-20220731_cal.xml	Edgar Link	unprocessable
rfl-20220731_def.xml	Edgar Link	unprocessable
rfl-20220731_pre.xml	Edgar Link	unprocessable
rfl-20220731_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RFL
Rafael Holdings Inc Stock $rfl

2022 Q3 Form 10-K Financial Statement

#000121390022067711 Filed on October 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RFL Rafael Holdings Inc Stock $rfl

2022 Q3 Form 10-K Financial Statement

#000121390022067711 Filed on October 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RFL
Rafael Holdings Inc Stock $rfl